Acute Respiratory Distress Network (ARDSNet) Study 05 Fluid and Catheter Treatment Trial (FACTT) - Catalog
Acute Respiratory Distress Network (ARDSNet) Study 05 Fluid and Catheter Treatment Trial (FACTT)
HLB00650808a
ARDSNet-FACTT
AR5
False
True
True
Coded
http://www.ardsnet.org/
False
Clinical Trial
Open BioLINCC Study
Both
Procedure: Low Tidal Volume VentilationProcedure: Positive End-Expiratory PressureDrug: LysofyllineDrug: MethylprednisoloneDrug: KetoconazoleProcedure: Fluid ManagementProcedure: Pulmonary Artery Catheter
2009-10-01
2010-04-09
2008-10-13
2006-08-24
2000-2005
DLD
Lung
non-HIV
non-COVID
9348
0
No
No
Yes
No
Yes
Yes
Use of biospecimens in genetic research is tiered to (1) research in acute respiratory distress syndrome (ARDS) and related disorders, or (2) research in other medical conditions. Biospecimens cannot be used directly to produce commercial products.
ALI
ARDS
Acute Lung Injury
Lung Diseases
Respiratory Distress Syndrome, Adult
This study evaluated the benefits and risks of Pulmonary Artery Catheters (PACs) in patients with established acute lung injury in a trial comparing hemodynamic management guided by a PAC with hemodynamic management guided by a central venous catheter (CVC) using an explicit management protocol.
Optimal fluid management in patients with acute lung injury is unknown. Diuresis or fluid restriction may improve lung function but could jeopardize extrapulmonary organ perfusion.
This randomized study compared a conservative and a liberal strategy of fluid management using explicit protocols applied for seven days in 1000 patients with acute lung injury. The primary end point was death at 60 days. Secondary end points included the number of ventilator-free days and organ-failure-free days and measures of lung physiology.
Although there was no significant difference in the primary outcome of 60-day mortality, the conservative strategy of fluid management was associated with improved lung function and shortened the duration of mechanical ventilation and intensive care without increasing nonpulmonary-organ failures. These results support the use of a conservative strategy of fluid management in patients with acute lung injury. (NEJM June 15, 2006; Vol 354, No. 24, pp 2564-75; NEJM May 25, 2006; Vol 354, No. 21, pp 2213-24)
DNA
Plasma
Serum
Acute Respiratory Distress Network (ARDSNet)
The study population available in BioLINCC study data may be lower than total study enrollment due to Informed Consent restrictions and other factors.
-
Subjects
PAC/fluid liberal: 252
PAC/fluid conservative: 261
CVC/fluid liberal: 245
CVC/fluid conservative: 242
Last Modified: June 22, 2022, 10:54 a.m. -
Age
PAC/Fluid
Liberal
PAC/Fluid
Conservative
CVC/Fluid
Liberal
CVC/Fluid
Conservative
All
N
%
N
%
N
%
N
%
N
%
16-20
3
1.19
6
2.30
7
2.86
8
3.31
24
2.40
21-25
8
3.17
14
5.36
13
5.31
10
4.13
45
4.50
26-30
16
6.35
10
3.83
14
5.71
11
4.55
51
5.10
31-35
23
9.13
19
7.28
16
6.53
15
6.20
73
7.30
36-40
29
11.51
29
11.11
29
11.84
23
9.50
110
11.00
41-45
30
11.90
34
13.03
28
11.43
24
9.92
116
11.60
46-50
27
10.71
31
11.88
29
11.84
34
14.05
121
12.10
51-55
27
10.71
30
11.49
27
11.02
31
12.81
115
11.50
56-60
23
9.13
26
9.96
26
10.61
20
8.26
95
9.50
61-65
17
6.75
16
6.13
15
6.12
23
9.50
71
7.10
66-70
15
5.95
15
5.75
17
6.94
8
3.31
55
5.50
71-75
15
5.95
13
4.98
11
4.49
17
7.02
56
5.60
76-80
12
4.76
8
3.07
8
3.27
9
3.72
37
3.70
81-85
3
1.19
4
1.53
3
1.22
9
3.72
19
1.90
86-90
4
1.59
6
2.30
2
0.82
.
.
12
1.20
Last Modified: June 22, 2022, 10:54 a.m. -
Sex
PAC/Fluid
Liberal
PAC/Fluid
Conservative
CVC/Fluid
Liberal
CVC/Fluid
Conservative
All
N
%
N
%
N
%
N
%
N
%
Female
141
55.95
134
51.34
130
53.06
129
53.31
534
53.40
Male
111
44.05
127
48.66
115
46.94
113
46.69
466
46.60
Last Modified: June 22, 2022, 10:54 a.m. -
Race
PAC/Fluid
Liberal
PAC/Fluid
Conservative
CVC/Fluid
Liberal
CVC/Fluid
Conservative
All
N
%
N
%
N
%
N
%
N
%
White non-Hispanic
160
63.49
173
66.28
153
62.45
155
64.05
641
64.10
Black non-Hispanic
61
24.21
51
19.54
57
23.27
48
19.83
217
21.70
Other
31
12.30
37
14.18
35
14.29
39
16.12
142
14.20
Last Modified: June 22, 2022, 10:54 a.m.
Please note that biospecimen availability is subject to review by the NHLBI, BioLINCC, and the NHLBI Biorepository. Certain biospecimens may not be made available for your request.
Section 3.0 of the BioLINCC Handbook
describes the components of the review process.
-
Material Types
-
General Freeze/Thaw Status
-
Visits (Vials)
Last Modified: Nov. 1, 2022, 9:39 a.m. -
Visits (Subjects)
Last Modified: Nov. 1, 2022, 9:39 a.m.